Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Cantargia AB ( (SE:CANTA) ).
Cantargia AB announced the release of its interim report for the first half of 2025, scheduled for August 21, 2025. The company will host an audiocast and teleconference to present the report, featuring insights from the interim CEO, CBO, and CFO, followed by a Q&A session. This event is significant for stakeholders as it provides an update on Cantargia’s operational progress and strategic direction, potentially impacting its market positioning and investor relations.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program involves the antibody nadunolimab (CAN04), which is being clinically studied mainly in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also has a second development program, CAN10, targeting serious autoimmune and inflammatory diseases.
Average Trading Volume: 6,259,348
Technical Sentiment Signal: Buy
Current Market Cap: SEK760.8M
For an in-depth examination of CANTA stock, go to TipRanks’ Overview page.